<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="case-report"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Ther Adv Neurol Disord</journal-id><journal-id journal-id-type="iso-abbrev">Ther Adv Neurol Disord</journal-id><journal-id journal-id-type="publisher-id">TAN</journal-id><journal-id journal-id-type="hwp">sptan</journal-id><journal-title-group><journal-title>Therapeutic Advances in Neurological Disorders</journal-title></journal-title-group><issn pub-type="ppub">1756-2856</issn><issn pub-type="epub">1756-2864</issn><publisher><publisher-name>SAGE Publications</publisher-name><publisher-loc>Sage UK: London, England</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">PMC9437258</article-id><article-id pub-id-type="doi">10.1177/17562864221102842</article-id><article-id pub-id-type="publisher-id">10.1177_17562864221102842</article-id><article-categories><subj-group subj-group-type="heading"><subject>Case Series</subject></subj-group></article-categories><title-group><article-title>Hyperacute treatment of childhood stroke in Lyme neuroborreliosis:
report of two cases and systematic review of the literature</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3327-3550</contrib-id><name><surname>Philipps</surname><given-names>Joerg</given-names></name><xref rid="corresp1-17562864221102842" ref-type="corresp"/><aff id="aff1-17562864221102842">Department of Neurology and Neurogeriatrics,
Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Hans-Nolte-Str. 1,
D-32429 Minden, Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Erdlenbruch</surname><given-names>Bernhard</given-names></name><aff id="aff2-17562864221102842">Department of Pediatrics, Johannes Wesling
Klinikum Minden, Ruhr-University Bochum, Minden, Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Supervision">Supervision</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Kuschnerow</surname><given-names>Michael</given-names></name><aff id="aff3-17562864221102842">Department of Diagnostic and Interventional
Radiology, Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Minden,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Jagoda</surname><given-names>Sunil</given-names></name><aff id="aff4-17562864221102842">Department of Anesthesiology and Intensive
Care, Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Minden,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Salihaj</surname><given-names>Blerta</given-names></name><aff id="aff5-17562864221102842">Department of Neurology and Neurogeriatrics,
Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Minden,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Glahn</surname><given-names>Joerg</given-names></name><aff id="aff6-17562864221102842">Department of Neurology and Neurogeriatrics,
Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Minden,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Supervision">Supervision</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib><contrib contrib-type="author"><name><surname>Schellinger</surname><given-names>Peter Dieter</given-names></name><aff id="aff7-17562864221102842">Department of Neurology and Neurogeriatrics,
Johannes Wesling Klinikum Minden, Ruhr-University Bochum, Minden,
Germany</aff><role content-type="https://dictionary.casrai.org/Contributor_Roles/Conceptualization">Conceptualization</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Investigation">Investigation</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Methodology">Methodology</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Supervision">Supervision</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_original_draft">Writing original draft</role><role content-type="https://dictionary.casrai.org/Contributor_Roles/Writing_review_editing">Writing review editing</role></contrib></contrib-group><author-notes><corresp id="corresp1-17562864221102842">
<email>joerg.philipps@rub.de</email>
</corresp></author-notes><pub-date pub-type="epub"><day>20</day><month>6</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>15</volume><elocation-id>17562864221102842</elocation-id><history><date date-type="received"><day>17</day><month>2</month><year>2022</year></date><date date-type="accepted"><day>5</day><month>5</month><year>2022</year></date></history><permissions><copyright-statement>&#x000a9; The Author(s), 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder content-type="sage">SAGE Publications Ltd unless otherwise noted.
Manuscript content on this site is licensed under Creative Commons
Licenses</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the Creative Commons
Attribution-NonCommercial 4.0 License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which
permits non-commercial use, reproduction and distribution of the work
without further permission provided the original work is attributed as
specified on the SAGE and Open Access page (<ext-link ext-link-type="uri" xlink:href="https://us.sagepub.com/en-us/nam/open-access-at-sage">https://us.sagepub.com/en-us/nam/open-access-at-sage</ext-link>).</license-p></license></permissions><abstract><p>The safety and efficacy of hyperacute reperfusion therapies in childhood stroke
due to focal cerebral arteriopathy (FCA) with an infectious and inflammatory
component is unknown. Lyme neuroborreliosis (LNB) is reported as a rare cause of
childhood stroke. Intravenous thrombolysis (IVT) and endovascular therapy (EVT)
have not been reported in LNB-associated stroke in children. We report two
children with acute stroke associated with LNB who underwent hyperacute stroke
treatment. A systematic review of the literature was performed to identify case
reports of LNB-associated childhood stroke over the last 20&#x02009;years. Patient 1
received IVT within 73&#x02009;min after onset of acute hemiparesis and dysarthria;
medulla oblongata infarctions were diagnosed on magnetic resonance imaging
(MRI). Patient 2 received successful EVT 6.5&#x02009;hr after onset of progressive
tetraparesis, coma, and decerebrate posturing caused by basilar artery occlusion
with bilateral pontomesencephalic infarctions. Both patients exhibited a
lymphocytic cerebrospinal fluid (CSF) pleocytosis and elevated antibody index
(AI) to <italic toggle="yes">Borrelia burgdorferi</italic>. Antibiotic treatment, steroids,
and platelet inhibitors including tirofiban infusion in patient 2 were
administered. No side effects were observed. On follow-up, patient 1 showed good
recovery and patient 2 was asymptomatic. In the literature, 12 cases of
LNB-associated childhood stroke were reported. LNB-associated infectious and
inflammatory FCA is not a medical contraindication for reperfusion therapies in
acute childhood stroke. Steroids are discussed controversially in inflammatory
FCA due to LNB. Intensified antiplatelet regimes may be considered; secondary
prophylaxis with acetyl-salicylic acid (ASA) is recommended because of a high
risk of early stroke recurrence.</p></abstract><kwd-group><kwd>acute treatment</kwd><kwd>childhood stroke</kwd><kwd>endovascular treatment</kwd><kwd>focal cerebral arteriopathy</kwd><kwd>intravenous thrombolysis</kwd><kwd>Lyme neuroborreliosis</kwd></kwd-group><funding-group specific-use="FundRef"><award-group id="award1-17562864221102842"><funding-source id="funding1-17562864221102842">
<institution-wrap><institution>Open Access Publication Funds of the Ruhr-University
Bochum</institution><institution-id/></institution-wrap>
</funding-source></award-group></funding-group><custom-meta-group><custom-meta><meta-name>cover-date</meta-name><meta-value>January-December 2022</meta-value></custom-meta><custom-meta><meta-name>typesetter</meta-name><meta-value>ts1</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="section1-17562864221102842"><title>Introduction</title><p>Childhood arterial ischemic stroke (AIS) is frequently associated with focal cerebral
arteriopathy (FCA).<sup>
<xref rid="bibr1-17562864221102842" ref-type="bibr">1</xref>
</sup> Lyme disease, the symptomatic arthropod-borne infection with <italic toggle="yes">Borrelia
burgdorferi</italic> sensu lato, may present with various manifestations in the
peripheral and central nervous system (CNS), including meningovascular involvement,
that are denoted as Lyme neuroborreliosis (LNB). Although a rare event,
cerebrovascular manifestations of LNB have been reported as potential cause of
childhood AIS, especially in European regions with high prevalence of
<italic toggle="yes">Borrelia garinii</italic>.<sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup> Management of childhood AIS due to LNB consists of early antibiotic
treatment, usually a third-generation cephalosporine.<sup><xref rid="bibr3-17562864221102842" ref-type="bibr">3</xref>,<xref rid="bibr4-17562864221102842" ref-type="bibr">4</xref></sup> Platelet inhibition with
acetyl-salicylic acid (ASA) as secondary prevention and steroids as treatment of
inflammatory arteriopathy have been discussed in the literature.<sup><xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>,<xref rid="bibr5-17562864221102842" ref-type="bibr">5</xref></sup> The safety and efficacy of
intravenous thrombolysis (IVT) and endovascular therapy (EVT) in the setting of
childhood FCA, especially with an infectious and inflammatory component, is unknown.<sup>
<xref rid="bibr1-17562864221102842" ref-type="bibr">1</xref>
</sup> We present two cases of hyperacute stroke treatment of childhood AIS due to
LNB-associated FCA. Feasibility, benefits, and potential risks of hyperacute
treatment of LNB-associated childhood stroke are discussed, and a review of case
reports with a focus on acute treatment is provided.</p></sec><sec id="section2-17562864221102842"><title>Methods</title><sec id="section3-17562864221102842"><title>Patients</title><p>Two children treated at the Johannes-Wesling-Klinikum Minden, University Hospital
of the Ruhr-University Bochum, Germany, in 2020 and 2021 are reported.
Consensus-based clinical case report (CARE) guidelines were applied to present
the two case reports.<sup>
<xref rid="bibr6-17562864221102842" ref-type="bibr">6</xref>
</sup> The patients&#x02019; legal representatives (parents) provided written informed
consent to the publication. Further institutional approval was waived in
accordance with German ethical regulations on case reports.</p></sec><sec id="section4-17562864221102842"><title>Literature review</title><p>A systematic review of the online database MEDLINE/PubMed using the search
algorithm [(neuroborreliosis OR Lyme OR LNB) AND stroke AND treatment AND
(children OR child) AND case AND report, year&#x02004;&#x0003e;&#x02004;2001] was carried out.
References in each identified article were reviewed to find additional published
case reports. The identified articles were further processed according to the
preferred reporting items for systematic reviews and meta-anlyses (PRISMA) checklist<sup>
<xref rid="bibr7-17562864221102842" ref-type="bibr">7</xref>
</sup> in order to identify original case reports of childhood AIS as
manifestations of LNB in the last 20&#x02009;years.</p></sec></sec><sec sec-type="results" id="section5-17562864221102842"><title>Results</title><sec id="section6-17562864221102842"><title>Case description 1</title><p>A 13-year-old boy presented 30&#x02009;min after symptom onset with a sudden weakness of
the right side and slurred speech. In the 3&#x02009;weeks before, he had complained
about headache, mild flu-like symptoms, fatigue, and myalgia. Neurological
examination revealed a right directional nystagmus, dysarthria, brachiofacial
hemiparesis, hemihypesthesia, and extensor plantar sign on the right side. The
pediatric National Institute of Health stroke scale score (pedNIHSS) was 10.
Emergency laboratory examinations were normal.</p><p>Cerebral magnetic resonance imaging [MRI; DWI/ADC (diffusion-weighted
imaging/apparent diffusion coefficient), FLAIR (fluid-attenuated inversion
recovery, SWI (susceptibility weighted imaging), and TOF (time-of-flight)
angiography] showed a hyperintense area on DWI with ADC restriction in the
medulla oblongata on the left side; FLAIR and SWI were normal. Imaging was
affected by metal artifacts generated by the patient&#x02019;s orthodontic braces.</p><p>Systemic IVT was started 73&#x02009;min after onset of symptoms in the MRI with a total
dose of 45&#x02009;mg alteplase in 1&#x02009;h (0.9&#x02009;mg/kg, 10% as initial bolus). Door-to-needle
time was 43&#x02009;min. Extracranial duplex sonography and transcranial color-coded
duplex sonography (TCCS) revealed a slightly reduced flow velocity in the left
vertebral artery (extracranial v2 segment and intracranial v4 segment) and a
reduced diameter of the left vertebral artery compatible with congenital
hypoplasia of the left vertebral artery. Flow in the extra- and intracerebral
blood vessels was otherwise normal.</p><p>Follow-up MRI (DWI/ADC, T1, FLAIR, SWI, and gadolinium-enhanced MR-angiography)
on day 1 (after removal of the braces) showed a hyperintense area on DWI with
ADC restriction and very subtle hyperintensity in FLAIR in the medulla oblongata
on the left side. Gadolinium-enhanced MR-angiography revealed a minimum
irregularity in the diameter of the proximal basilar artery (BA) and a reduced
diameter of the left vertebral artery (<xref rid="fig1-17562864221102842" ref-type="fig">Figure 1</xref>). Axial T1 weighted images of
the neck showed no signs of dissection. PedNIHSS 24&#x02009;h after IVT was 10.</p><fig position="float" id="fig1-17562864221102842"><label>Figure 1.</label><caption><p>Patient 1, MRI on day 1: DWI (a), ADC (b), FLAIR-MRI (c), and
gadolinium-enhanced MR-angiography (d): DWI-hyperintensity, ADC
restriction in the left medulla oblongata, and minimum irregularity in
the diameter of the proximal basilar artery (arrow).</p></caption><graphic xlink:href="10.1177_17562864221102842-fig1" position="float"/></fig><p>Lumbar puncture on day 2 yielded a lymphocytic cerebrospinal fluid (CSF)
pleocytosis, elevated protein, and intrathecal <italic toggle="yes">B. burgdorferi</italic>
IgG antibody synthesis (see <xref rid="table1-17562864221102842" ref-type="table">Table 1</xref>). Other pathogens were
excluded [severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2),
Tick-borne encephalitis (TBE), Varicella-Zoster Virus (VZV), herpes simplex
virus (HSV), Epstein&#x02013;Barr virus (EBV), cytomegalovirus (CMV), <italic toggle="yes">Treponema
pallidum, Mycobacterium tuberculosis</italic>, human immunodeficiency virus
(HIV), Parainfluenza Virus, Parvovirus B19, Candida, Mycoplasma,
<italic toggle="yes">Listeria monocytogenes</italic>]. Antibiotic treatment was started
with cefotaxime (6&#x02009;g/day for 14&#x02009;days), acyclovir, and ampicillin being stopped
after negative results for HSV/VZV and <italic toggle="yes">L. monocytogenes</italic>. A
steroid pulse of 500&#x02009;mg methylprednisolone was administered for 5&#x02009;days, then
50&#x02009;mg of prednisolone were given per os and tapered over a period of 1&#x02009;month.
ASA 100&#x02009;mg daily was administered continuously.</p><table-wrap position="float" id="table1-17562864221102842"><label>Table 1.</label><caption><p>LNB-related CSF and serum laboratory results.</p></caption><alternatives><graphic xlink:href="10.1177_17562864221102842-table1" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Parameter</th><th align="left" rowspan="1" colspan="1">Normal value</th><th align="left" rowspan="1" colspan="1">Unit</th><th align="left" rowspan="1" colspan="1">Patient 1, day 2</th><th align="left" rowspan="1" colspan="1">Patient 1, day 18</th><th align="left" rowspan="1" colspan="1">Patient 2, day 0</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">CSF cell count</td><td rowspan="1" colspan="1">(&#x0003c;4)</td><td rowspan="1" colspan="1">[/&#x000b5;l]</td><td rowspan="1" colspan="1">155</td><td rowspan="1" colspan="1">36</td><td rowspan="1" colspan="1">45</td></tr><tr><td rowspan="1" colspan="1">CSF cytology</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">[% lymphomonocytes/granulocytes/plasma cells]</td><td rowspan="1" colspan="1">100/0/0</td><td rowspan="1" colspan="1">97/3/0</td><td rowspan="1" colspan="1">95/1/4</td></tr><tr><td rowspan="1" colspan="1">CSF protein</td><td rowspan="1" colspan="1">(&#x0003c;450)</td><td rowspan="1" colspan="1">[mg/l]</td><td rowspan="1" colspan="1">1070.7</td><td rowspan="1" colspan="1">325.8</td><td rowspan="1" colspan="1">413.5</td></tr><tr><td rowspan="1" colspan="1">CSF lactate</td><td rowspan="1" colspan="1">(&#x0003c;2.1)</td><td rowspan="1" colspan="1">[mmol/l]</td><td rowspan="1" colspan="1">2.67</td><td rowspan="1" colspan="1">2.17</td><td rowspan="1" colspan="1">1.68</td></tr><tr><td rowspan="1" colspan="1">IgG intrathecal fraction</td><td rowspan="1" colspan="1">(&#x0003c;5)</td><td rowspan="1" colspan="1">[%]</td><td rowspan="1" colspan="1">46</td><td rowspan="1" colspan="1">45</td><td rowspan="1" colspan="1">25</td></tr><tr><td rowspan="1" colspan="1">IgM intrathecal fraction</td><td rowspan="1" colspan="1">(&#x0003c;5)</td><td rowspan="1" colspan="1">[%]</td><td rowspan="1" colspan="1">63</td><td rowspan="1" colspan="1">65</td><td rowspan="1" colspan="1">90</td></tr><tr><td rowspan="1" colspan="1">Albumin quotient</td><td rowspan="1" colspan="1">(L/S&#x02009;&#x000d7;&#x02009;10&#x000b3;, &#x0003c;4.9)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">13.7</td><td rowspan="1" colspan="1">3.7</td><td rowspan="1" colspan="1">5.8</td></tr><tr><td rowspan="1" colspan="1">CSF CXCL13</td><td rowspan="1" colspan="1">(&#x0003c;30)</td><td rowspan="1" colspan="1">[pg/ml]</td><td rowspan="1" colspan="1">311.50</td><td rowspan="1" colspan="1">Not controlled</td><td rowspan="1" colspan="1">452.90</td></tr><tr><td rowspan="1" colspan="1">B.b.-specific AI IgG</td><td rowspan="1" colspan="1">(&#x0003c;1.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">40.5</td><td rowspan="1" colspan="1">7.9</td><td rowspan="1" colspan="1">25.0</td></tr><tr><td rowspan="1" colspan="1">B.b.-specific AI IgM</td><td rowspan="1" colspan="1">(&#x0003c;1.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">n.d.</td><td rowspan="1" colspan="1">n.d.</td><td rowspan="1" colspan="1">47.0</td></tr><tr><td rowspan="1" colspan="1">B.b. (VlsE) AI IgG</td><td rowspan="1" colspan="1">(&#x0003c;1.5)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">40.2</td><td rowspan="1" colspan="1">8.0</td><td rowspan="1" colspan="1">17.3</td></tr><tr><td rowspan="1" colspan="1">Serum B.b. AB IgG</td><td rowspan="1" colspan="1">(&#x0003c;20)</td><td rowspan="1" colspan="1">[U/ml]</td><td rowspan="1" colspan="1">911</td><td rowspan="1" colspan="1">3632</td><td rowspan="1" colspan="1">61</td></tr><tr><td rowspan="1" colspan="1">Serum B.b. AB IgM</td><td rowspan="1" colspan="1">(&#x0003c;20)</td><td rowspan="1" colspan="1">[U/ml]</td><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">27</td></tr><tr><td rowspan="1" colspan="1">Serum VlsE AB IgG</td><td rowspan="1" colspan="1">(&#x0003c;10)</td><td rowspan="1" colspan="1">[U/ml]</td><td rowspan="1" colspan="1">399</td><td rowspan="1" colspan="1">1425</td><td rowspan="1" colspan="1">110</td></tr><tr><td rowspan="1" colspan="1">B.b.-specific bands detected in immunoblot<sup>
<xref rid="table-fn3-17562864221102842" ref-type="table-fn">a</xref>
</sup></td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IgG: p43, p14, Osp17, OspC, VlsE</td><td rowspan="1" colspan="1">Not controlled</td><td rowspan="1" colspan="1">IgM: p41, OspC; IgG: VlsE</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn1-17562864221102842"><p>AB, antibody; AI, antibody index; B.b., <italic toggle="yes">Borrelia
burgdorferi</italic>; CSF, cerebrospinal fluid; LNB, Lyme
neuroborreliosis; n.d., not detectable.</p></fn><fn id="table-fn2-17562864221102842"><p>AI calculations (using the Q-Lim ratio) and B.b. serodiagnosis
(standard two-tier testing, enzyme immunoassay followed by
immunoblot) were performed by an accredited microbiology laboratory
according to the current guidelines.<sup>
<xref rid="bibr3-17562864221102842" ref-type="bibr">3</xref>
</sup></p></fn><fn id="table-fn3-17562864221102842"><label>a</label><p>Microarray immunoblot (ViraChip<sup>&#x000ae;</sup>, Viramed Biotech,
Germany).</p></fn></table-wrap-foot></table-wrap><p>On day 3, dysarthria worsened and a marked dysphagia developed. Hiccup occurred
constantly, hemiparesis and nystagmus were unchanged, and pedNIHSS was 12. He
developed a febrile episode and an ampicillin rash.</p><p>A third MRI showed a new right side medulla oblongata infarct; the left side
medulla oblongata DWI/FLAIR lesion was slightly larger than in the second MRI.
In a control lumbar puncture on day 18, there was a mild lymphomonocytic
pleocytosis and normal protein; <italic toggle="yes">B. burgdorferi</italic>-specific
antibody index (AI) was again positive (<xref rid="table1-17562864221102842" ref-type="table">Table 1</xref>). Further extensive laboratory
examinations, including thrombophilia, were normal. Transesophageal
echocardiography and electrocardiogram were normal. The patient and his family
live in northern Germany, frequent hiking tours in the forest were reported, but
no tick bites or erythema were recorded.</p><p>PedNIHSS on day 7 was 9; dysarthria and dysphagia slowly improved. On discharge
to neurological rehabilitation, he was able to feed without a nasogastric tube
but unable to walk. On follow-up 9&#x02009;months later, he was able to walk unaided,
pedNIHSS was 2, modified Rankin Scale (mRS) 2, and Barthel Index 95.
Extracranial duplex sonography and TCCS were unchanged showing hypoplasia of the
left vertebral artery and were otherwise normal. Platelet inhibition with ASA
100&#x02009;mg/day was the only ongoing medication. He is able to live with his family
and attend his former school.</p></sec><sec id="section7-17562864221102842"><title>Case description 2</title><p>A 6-year-old boy with a history of headache and fatigue for 4&#x02009;weeks and vertigo
on the day of admission presented to the emergency department with a worsening
impairment of consciousness, beginning 2&#x02009;h before. He was unable to speak and
could not walk. Neurological examination revealed a progressive coma (worst
Glasgow coma scale (GCS) 7, pedNIHSS 32), a rotating downbeat nystagmus, left
ptosis, anisocoria, severe dysarthria, left hemiparesis, and then tetraplegia
with bilateral extensor plantar sign. The patient exhibited intermittent
decerebrate posturing. The accompanying father reported a family history of a
heterozygous factor V Leiden mutation.</p><p>Cranial computed tomography (CCT) showed a hyperdense BA sign and was otherwise
normal. Brain MRI including diffusion-weighted and ADC maps, three-dimensional
TOF MR-angiography, SWI, and FLAIR images revealed acute bilateral
pontomesencephalic DWI hyperintensities/ADC restrictions caused by extensive
thrombotic occlusion (<xref rid="fig2-17562864221102842" ref-type="fig">Figure
2(a)&#x02013;(c)</xref>) of the BA. Thrombus formation was visualized in DWI and
FLAIR sequences as a hyperintense signal in the BA (<xref rid="fig2-17562864221102842" ref-type="fig">Figure 2(b)</xref> and (<xref rid="fig2-17562864221102842" ref-type="fig">d</xref>)) and as a blooming artifact
(susceptibility vessel sign) in SWI images (<xref rid="fig2-17562864221102842" ref-type="fig">Figure 2(e)</xref>).</p><fig position="float" id="fig2-17562864221102842"><label>Figure 2.</label><caption><p>Patient 2, MRI on admission: time-of-flight MR-angiography (a), DWI (b),
ADC (c), FLAIR (d), and SWI (e) images: basilar artery occlusion, acute
bilateral pontomesencephalic infarctions in DWI/ADC but not in FLAIR
images. Thrombus is visualized in FLAIR sequences as a hyperintense
signal in the basilar artery and as a blooming artifact (arrow) in SWI
images.</p></caption><graphic xlink:href="10.1177_17562864221102842-fig2" position="float"/></fig><p>Three-dimensional rotational digital subtraction angiography (3D-R-DSA) confirmed
total BA occlusion. EVT was successfully performed (Thrombolysis in cerebral
infarction scale TICI 3) using a 5F femoral access, an aspiration catheter as
first-line approach, and an Embotrap III<sup>&#x000ae;</sup> stent retriever. Small
fragments of a thrombus were retrieved after three attempts within the stent
retriever after injection of 5&#x02009;mg alteplase into the proximal end of the
thrombus. Door-to-groin time was 3.5&#x02009;h; recanalization and reappearance of
pontine branches were achieved 6.5&#x02009;h after onset of symptoms (<xref rid="fig3-17562864221102842" ref-type="fig">Figure 3</xref>). After EVT and
a final rotational scan to exclude a periprocedural hematoma, ASA 100&#x02009;mg IV
(intravenous) was given.</p><fig position="float" id="fig3-17562864221102842"><label>Figure 3.</label><caption><p>Patient 2: EVT with recanalization of the basilar artery (TICI 3) 6.5&#x02009;h
after onset of symptoms. Angiography in lateral (a) and
posterior&#x02013;anterior (b) view.</p></caption><graphic xlink:href="10.1177_17562864221102842-fig3" position="float"/></fig><p>Lumbar puncture had been performed directly before MRI and CSF showed a
lymphomonocytic pleocytosis; protein was normal. IgG and IgM AI for <italic toggle="yes">B.
burgdorferi</italic> were elevated (<xref rid="table1-17562864221102842" ref-type="table">Table 1</xref>). Polymerase chain reaction
(PCR) for HSV, VZV, and <italic toggle="yes">L. monocytogenes</italic> was negative. Further
laboratory examinations including Factor V Leiden mutation were normal.
Transthoracal echocardiography and electrocardiogram were normal. Living in
northern Germany, frequent playing in the forest and multiple tick bites without
erythema were reported.</p><p>Parallel to EVT, antibiotic treatment with cefotaxime, acyclovir, and ampicillin
was started, and dexamethasone 4&#x02009;mg IV was administered. Cefotaxime (3&#x02009;&#x000d7;&#x02009;1.3&#x02009;g
IV) continued for 16&#x02009;days, dexamethasone was stopped on day 3, prednisolone
30&#x02009;mg p.o. was given for 12&#x02009;days, and then tapered over a period of 4&#x02009;weeks.</p><p>A follow-up MRI 7&#x02009;h after EVT showed regression of pontomesencephalic DWI/ADC
lesions on the left but progression on the right side. Subtle bilateral
pontomesencephalic hyperintensities in FLAIR maps were visible. Subtotal BA
reocclusion and stenosis of the left posterior cerebral artery (PCA; P1 segment)
were detected on TOF-MR-angiography (MRA) (<xref rid="fig4-17562864221102842" ref-type="fig">Figure 4</xref>). TCCS revealed a highly
reduced and turbulent, but orthograde flow in the BA; a high resistance index in
both vertebral arteries (extra- and intracranial); and an elevated flow velocity
in the PCA (P1 segment). After interdisciplinary discussion of treating
neurologist, pediatrician, interventional neuroradiologist, and parents, the
decision was made against a second attempt of EVT. Instead, an off-label therapy
with IV tirofiban (Aggrastat<sup>&#x000ae;</sup> 0.4&#x02009;&#x000b5;g/kg/min for 30&#x02009;min, then
0.1&#x02009;&#x000b5;g/kg/min for 72&#x02009;h) was started.</p><fig position="float" id="fig4-17562864221102842"><label>Figure 4.</label><caption><p>Patient 2: time-of-flight MR-angiography: subtotal basilar artery
reocclusion. The vertebral arteries and the top of the basilary are
still visible (in contrast to <xref rid="fig2-17562864221102842" ref-type="fig">Figure 2(a)</xref>).</p></caption><graphic xlink:href="10.1177_17562864221102842-fig4" position="float"/></fig><p>The patient was extubated 6&#x02009;h after the second MRI and was able to communicate
and move all extremities. He complained of double vision, and showed a left
ptosis and a left side ataxia. After using a walking frame for children, he was
able to walk unaided on day 5; on day 10, the pedNIHSS was 0. A third MRI on day
8 revealed stable bilateral pontomesencephalic hyperintensities, very subtle on
FLAIR images, reduced flow in the proximal BA, and stenosis of the left P1
segment. Extracranial duplex sonography and TCCS results gradually improved
showing a normalized flow profile in both vertebral arteries and a reduced flow
in the BA. Signs of stenosis in the PCA and flow abnormalities in the BA
completely resolved on day 14; the patient was asymptomatic. He was discharged
with a medication of ASA 50&#x02009;mg/day and prednisolone 15&#x02009;mg/day. Steroids had been
tapered as scheduled in week 5, ASA 50&#x02009;mg/day continued. On follow-up visits
6&#x02009;weeks and 5&#x02009;months after stroke, the patient was asymptomatic (pedNIHSS 0, mRS
0, Barthel 100); extracranial duplex sonography and TCCS were normal. The
patient lives with his family and can carry out all normal activities.</p></sec><sec id="section8-17562864221102842"><title>Review of the literature</title><p>The systematic review of the online database MEDLINE/PubMed yielded 11 articles.
Two articles not matching exactly the area of interest were excluded. The
remaining articles contained 12 original case reports of LNB-associated
childhood AIS.<sup><xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>,<xref rid="bibr8-17562864221102842" ref-type="bibr">8</xref><xref rid="bibr9-17562864221102842" ref-type="bibr"/><xref rid="bibr10-17562864221102842" ref-type="bibr"/><xref rid="bibr11-17562864221102842" ref-type="bibr"/><xref rid="bibr12-17562864221102842" ref-type="bibr"/><xref rid="bibr13-17562864221102842" ref-type="bibr"/><xref rid="bibr14-17562864221102842" ref-type="bibr"/>&#x02013;<xref rid="bibr15-17562864221102842" ref-type="bibr">15</xref></sup> Hyperacute reperfusion
therapies are not reported. The main characteristics of the published cases are
summarized in <xref rid="table2-17562864221102842" ref-type="table">Table
2</xref>.</p><table-wrap position="float" id="table2-17562864221102842"><label>Table 2.</label><caption><p>Stroke characteristics and treatment of published case reports of
LNB-associated childhood AIS in the last 20&#x02009;years.</p></caption><alternatives><graphic xlink:href="10.1177_17562864221102842-table2" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/><col align="char" char="." span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Author(s)</th><th align="left" rowspan="1" colspan="1">Sex<break/>Age</th><th align="left" rowspan="1" colspan="1">Stroke symptoms</th><th align="left" rowspan="1" colspan="1">Vascular pathology</th><th align="left" rowspan="1" colspan="1">Antibiotic treatment</th><th align="left" rowspan="1" colspan="1">Secondary prophylaxis</th><th align="left" rowspan="1" colspan="1">Steroid treatment</th><th align="left" rowspan="1" colspan="1">Outcome</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">Klingebiel <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr8-17562864221102842" ref-type="bibr">8</xref>
</sup></td><td rowspan="1" colspan="1">Female<break/>6&#x02009;years</td><td rowspan="1" colspan="1">Hemiparesis</td><td rowspan="1" colspan="1">ICA, ACA stenosis<break/>MCA branch occlusion</td><td rowspan="1" colspan="1">Ceftriaxone<break/>100&#x02009;mg/kg/day, 14&#x02009;days
pseudo-cholelithiasis, then cefotaxime 7&#x02009;days</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">Hemiparesis concentration deficit after 6&#x02009;months
asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Cox <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr9-17562864221102842" ref-type="bibr">9</xref>
</sup></td><td rowspan="1" colspan="1">Female<break/>12&#x02009;years</td><td rowspan="1" colspan="1">Hemiparesis<break/>Facial paresis</td><td rowspan="1" colspan="1">ACA, MCA stenosis</td><td rowspan="1" colspan="1">Ceftriaxone 2&#x02009;g/day<break/>30&#x02009;days</td><td rowspan="1" colspan="1">ASA<break/>38&#x02009;mg/day</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">No follow-up reported</td></tr><tr><td rowspan="1" colspan="1">R&#x000e9;nard <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr10-17562864221102842" ref-type="bibr">10</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>11&#x02009;years</td><td rowspan="1" colspan="1">Hemiparesis<break/>Ataxia<break/>Aphasia</td><td rowspan="1" colspan="1">BA, MCA irregularity</td><td rowspan="1" colspan="1">Ceftriaxone for 21&#x02009;days</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">No follow-up reported</td></tr><tr><td rowspan="1" colspan="1">Lebas <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr11-17562864221102842" ref-type="bibr">11</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>8&#x02009;years</td><td rowspan="1" colspan="1">Somnolence<break/>Hemiparesis</td><td rowspan="1" colspan="1">BA irregularity enhancement of vessel wall</td><td rowspan="1" colspan="1">Ceftriaxone for 28&#x02009;days</td><td rowspan="1" colspan="1">Oral antiplatelet</td><td rowspan="1" colspan="1">Methylprednisolone 30&#x02009;mg/kg pulses 3&#x02009;days</td><td rowspan="1" colspan="1">Asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Kohns <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr12-17562864221102842" ref-type="bibr">12</xref>
</sup></td><td rowspan="1" colspan="1">Female<break/>5&#x02009;years</td><td rowspan="1" colspan="1">Hemiparesis<break/>Vertigo</td><td rowspan="1" colspan="1">MCA stenosis</td><td rowspan="1" colspan="1">Ceftriaxone 35&#x02009;mg/kg/day<break/>14&#x02009;days</td><td rowspan="1" colspan="1">ASA<break/>3&#x02009;mg/kg/day</td><td rowspan="1" colspan="1">Methylprednisolone 20&#x02009;mg/kg pulses 3&#x02009;days</td><td rowspan="1" colspan="1">Asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Kurian <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr13-17562864221102842" ref-type="bibr">13</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>12&#x02009;years</td><td rowspan="1" colspan="1">Facial paresis<break/>Hemiparesis</td><td rowspan="1" colspan="1">BA, MCA, ACA stenosis, enhancement of vessel wall</td><td rowspan="1" colspan="1">Ceftriaxone for 4&#x02009;weeks</td><td rowspan="1" colspan="1">ASA<break/>3&#x02009;mg/kg/day<break/>1&#x02009;year</td><td rowspan="1" colspan="1">Prednisone 2&#x02009;mg/kg/day<break/>4&#x02009;weeks</td><td rowspan="1" colspan="1">Asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Allen and Jungbluth<sup>
<xref rid="bibr14-17562864221102842" ref-type="bibr">14</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>15&#x02009;years</td><td rowspan="1" colspan="1">Leg weakness<break/>Ataxia<break/>Facial palsy</td><td rowspan="1" colspan="1">Stenosis posterior circulation</td><td rowspan="1" colspan="1">Ceftriaxone for 21&#x02009;days</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">Mild hemiplegia, abducens, and facial nerve palsy</td></tr><tr><td rowspan="1" colspan="1">Wittwer <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr15-17562864221102842" ref-type="bibr">15</xref>
</sup></td><td rowspan="1" colspan="1">Female<break/>5&#x02009;years</td><td rowspan="1" colspan="1">Wallenberg syndrome</td><td rowspan="1" colspan="1">None observed</td><td rowspan="1" colspan="1">Ceftriaxone for 6&#x02009;weeks</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">Improvement</td></tr><tr><td rowspan="1" colspan="1">Monteventi <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>12&#x02009;years</td><td rowspan="1" colspan="1">Confusion<break/>Hemiparesis</td><td rowspan="1" colspan="1">BA, PCA, MCA, ACA stenosis, enhancement of vessel wall</td><td rowspan="1" colspan="1">Ceftriaxone 2&#x02009;g/day<break/>28&#x02009;days</td><td rowspan="1" colspan="1">ASA 100&#x02009;mg/day<break/>6&#x02009;months</td><td rowspan="1" colspan="1">Prednisone 2&#x02009;mg/kg/day<break/>28&#x02009;days</td><td rowspan="1" colspan="1">Asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Monteventi <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>8&#x02009;years</td><td rowspan="1" colspan="1">Wallenberg syndrome</td><td rowspan="1" colspan="1">None observed</td><td rowspan="1" colspan="1">Ceftriaxone 2&#x02009;g/day<break/>21&#x02009;days</td><td rowspan="1" colspan="1">ASA 100&#x02009;mg/day<break/>6&#x02009;months</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">No follow-up reported</td></tr><tr><td rowspan="1" colspan="1">Monteventi <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>9&#x02009;years</td><td rowspan="1" colspan="1">Paresthesia<break/>Tremor</td><td rowspan="1" colspan="1">BA, VA stenosis</td><td rowspan="1" colspan="1">Ceftriaxone 2&#x02009;g/day<break/>14&#x02009;days</td><td rowspan="1" colspan="1">ASA 150&#x02009;mg/day<break/>8&#x02009;months</td><td rowspan="1" colspan="1">Prednisone 50&#x02009;mg/day<break/>5&#x02009;days tapered</td><td rowspan="1" colspan="1">Asymptomatic</td></tr><tr><td rowspan="1" colspan="1">Monteventi <italic toggle="yes">et al.</italic><sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup></td><td rowspan="1" colspan="1">Male<break/>13&#x02009;years</td><td rowspan="1" colspan="1">Wallenberg syndrome</td><td rowspan="1" colspan="1">VA stenosis</td><td rowspan="1" colspan="1">Ceftriaxone 2&#x02009;g/day<break/>14&#x02009;days</td><td rowspan="1" colspan="1">ASA 100&#x02009;mg/day</td><td rowspan="1" colspan="1">None</td><td rowspan="1" colspan="1">Sensory hemisyndrome</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="table-fn4-17562864221102842"><p>ACA, anterior cerebral artery; AIS, arterial ischemic stroke; ASA,
acetyl-salicylic acid; BA, basilar artery; ICA, internal carotid
artery; LNB, Lyme neuroborreliosis; MCA, middle cerebral artery;
PCA, posterior cerebral artery; VA, vertebral artery.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="section9-17562864221102842"><title>Discussion</title><p>We report two children with acute posterior circulation stroke associated with
European LNB who underwent hyperacute stroke treatment. Both patients live in an
endemic area (northern Germany) for <italic toggle="yes">B. burgdorferi</italic> sensu lato with
a high prevalence of <italic toggle="yes">B. garinii</italic> in tick nymphs,<sup>
<xref rid="bibr16-17562864221102842" ref-type="bibr">16</xref>
</sup> the latter being the predominant <italic toggle="yes">B. burgdorferi</italic> genotype in
children with LNB.<sup>
<xref rid="bibr17-17562864221102842" ref-type="bibr">17</xref>
</sup> They experienced headache and fatigue; patient 1 reported myalgia in the
weeks before admission. These otherwise unexplained symptoms, the lymphocytic CSF
pleocytosis, and elevated AI for <italic toggle="yes">B. burgdorferi</italic> (<xref rid="table1-17562864221102842" ref-type="table">Table 1</xref>) led to the
diagnosis of definite LNB according to the current guidelines.<sup><xref rid="bibr3-17562864221102842" ref-type="bibr">3</xref>,<xref rid="bibr4-17562864221102842" ref-type="bibr">4</xref></sup> Although CNS manifestations can
occur in early and late LNB, the presence of symptoms for less than 6&#x02009;months and the
elevated CSF CXCL 13 (Chemokine Ligand 13) confirm the diagnosis of an early stage
of LNB. Extensive diagnostic workup excluded other reasons for AIS; thus, childhood
AIS due to LNB-associated FCA was the final diagnosis.</p><sec id="section10-17562864221102842"><title>Antibiotic treatment</title><p>Both children were treated with the third-generation cephalosporine cefotaxime as
soon as the diagnosis of LNB was suspected. They presented as early LNB with
LNB-associated stroke and received 14 (patient 1) and 16 (patient 2) days of IV
antibiotic treatment. Duration of treatment ranged from 14&#x02009;days to 6&#x02009;weeks in
the literature. Current guidelines<sup><xref rid="bibr3-17562864221102842" ref-type="bibr">3</xref>,<xref rid="bibr4-17562864221102842" ref-type="bibr">4</xref></sup> recommend an early
antibiotic treatment with an IV third-generation cephalosporine or IV penicillin
G for childhood LNB and a treatment duration between 14&#x02009;days (early LNB) and
21&#x02009;days (late LNB). Oral doxycycline is an alternative for children over the age
of 8&#x02009;years. All cases (12/12) found in the literature were treated with an IV
third-generation cephalosporine, mostly ceftriaxone, none with doxycycline.</p></sec><sec id="section11-17562864221102842"><title>Acute thrombolytic and endovascular treatment</title><p>In both patients, the diagnosis of ischemic stroke was based on MRI in the
hyperacute phase showing the specific combination of DWI hyperintensity/ADC
restriction without signal abnormalities in FLAIR and SWI. As frequently
observed in hyperacute stroke, the DWI/ADC restrictions do not completely
represent the clinical picture. Patient 1 received IVT within the time window
and dosage approved for adult stroke patients. The diagnosis of LNB was not
suspected at the time of IVT; CSF examination (<xref rid="table1-17562864221102842" ref-type="table">Table 1</xref>) was done on day 2. Side
effects of IVT were not observed. A clinical deterioration of 2&#x02009;points in
pedNIHSS can be attributed to stroke progression confirmed on follow-up MRI,
although a febrile episode may as well have contributed to the clinical
deterioration. Follow-up showed an incomplete recovery with persisting
hemiparesis with significant impairment of hand function resulting in a pedNIHSS
of 2, mRS 2, and Barthel Index 95. There are no randomized, controlled trials
regarding IVT in acute childhood stroke; the TIPS Thrombolysis in pediatric
stroke (TIPS) trial<sup>
<xref rid="bibr18-17562864221102842" ref-type="bibr">18</xref>
</sup> had to be stopped because of low recruitment. In the absence of clinical
trial data, expert opinion supports the use of the adult dosage of 0.9&#x02009;mg/kg for IVT.<sup>
<xref rid="bibr19-17562864221102842" ref-type="bibr">19</xref>
</sup> Developmental differences in plasminogen levels suggest that equivalent
dosages might even be higher in children than in adults; thus, applying the
regular dose of alteplase might err on the safe rather than the dangerous side
with regard to hemorrhage risk.<sup>
<xref rid="bibr18-17562864221102842" ref-type="bibr">18</xref>
</sup> Recent retrospective data illustrate a very low risk of symptomatic
intracranial hemorrhage (sICH) sICH following IVT in childhood AIS.<sup><xref rid="bibr20-17562864221102842" ref-type="bibr">20</xref>,<xref rid="bibr21-17562864221102842" ref-type="bibr">21</xref></sup></p><p>Patient 2 received acute EVT, intra-arterial thrombolysis, and an intensified
antiplatelet therapy with IV tirofiban continued for 3&#x02009;days after early and
partial BA reocclusion. LNB was considered the most likely diagnosis at the time
of EVT; antibiotic and anti-inflammatory treatments were started simultaneously.
There were no side effects of EVT, alteplase injection into the thrombus, and
tirofiban therapy. Follow-up examination showed a complete recovery in spite of
imaging proof of subtle changes on FLAIR images corresponding to the initial
pontine DWI lesions.</p><p>EVT was considered safe and effective in a childhood subgroup analysis of the
Multicenter randomized clinical trial of endovascular treatment for acute
ischemic stroke in the Netherlands (MR CLEAN) study<sup>
<xref rid="bibr22-17562864221102842" ref-type="bibr">22</xref>
</sup> and in a recent case-based review.<sup>
<xref rid="bibr23-17562864221102842" ref-type="bibr">23</xref>
</sup> In the retrospective international multicenter Save ChildS Study,<sup>
<xref rid="bibr24-17562864221102842" ref-type="bibr">24</xref>
</sup> the safety of EVT in children was comparable to EVT results in clinical
trials for adults. No complications were reported, including six children with
FCA. In a single-center cohort in the United States,<sup>
<xref rid="bibr1-17562864221102842" ref-type="bibr">1</xref>
</sup> intracranial arteriopathy was found in 37% of cases; none of them
received IVT or EVT. In a case series of children who underwent thrombolytic
treatment including a review of the literature,<sup>
<xref rid="bibr25-17562864221102842" ref-type="bibr">25</xref>
</sup> stroke etiology included cardiogenic and paradoxical embolism,
spontaneous artery dissection, and stroke of unknown etiology. Children with
infectious AIS are not reported. Correspondingly, hyperacute treatment (IVT or
EVT) was not reported in the 12 cases with LNB-associated childhood AIS found in
the literature. A major factor affecting eligibility for hyperacute stroke
therapy in children is the presence of medical contraindications, accounting for
up to one-third of non-administered IVTs and EVTs.<sup>
<xref rid="bibr1-17562864221102842" ref-type="bibr">1</xref>
</sup> Inflammatory FCA in theory may increase the risk of bleeding
complications during EVT.<sup>
<xref rid="bibr26-17562864221102842" ref-type="bibr">26</xref>
</sup> Secondary vasculitis is mentioned among the exclusion criteria for IVT in
the TIPS study.<sup>
<xref rid="bibr18-17562864221102842" ref-type="bibr">18</xref>
</sup> The previous AHA scientific statement<sup>
<xref rid="bibr27-17562864221102842" ref-type="bibr">27</xref>
</sup> on treatment of childhood AIS classified LNB as an infectious (thus
secondary) vasculitis. The current American Heart Association (AHA) scientific statement<sup>
<xref rid="bibr19-17562864221102842" ref-type="bibr">19</xref>
</sup> introduces the more descriptive term of FCA-i (focal cerebral
arteriopathy inflammation type), denoting an infectious or parainfectious
process leading to localized vessel inflammation and secondary thrombus
formation and stroke.<sup>
<xref rid="bibr28-17562864221102842" ref-type="bibr">28</xref>
</sup> However, it does not mention LNB in this context. In addition to
inflammation of the vessel wall, thrombosis of the affected vessels has been
discussed in LNB.<sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup> This was observed in patient 2, as thrombotic BA occlusion led to a
hyperdense BA sign in CCT and to a blooming artifact (susceptibility vessel sign)<sup>
<xref rid="bibr29-17562864221102842" ref-type="bibr">29</xref>
</sup> on SWI images. The rapid clinical improvement after successful EVT with
TICI 3 recanalization and reappearance of pontine branches would not have been
observed had vessel inflammation been the only cause of BA occlusion.</p><p>In LNB, both in children and in adults, there is no clear semantic
differentiation between infectious cerebral vasculitis and FCA-i.<sup>
<xref rid="bibr13-17562864221102842" ref-type="bibr">13</xref>
</sup> In contrast to childhood stroke, in adults there is high-quality evidence
(double-blind, placebo-controlled studies) for IVT, EVT, and the combination of
both. Although acute reperfusion therapies have not been reported in
LNB-associated stroke in adults,<sup>
<xref rid="bibr5-17562864221102842" ref-type="bibr">5</xref>
</sup> both IVT and EVT can be administered following current guidelines
providing clear recommendations that are mostly independent of the putative
stroke etiology in the acute phase.</p></sec><sec id="section12-17562864221102842"><title>Platelet inhibition</title><p>Both patients reported in the present study received an early secondary stroke
prophylaxis with ASA, ongoing until follow-up. Before administration of ASA, ICH
as a potential complication of IVT and EVT with local alteplase injection was
excluded. In the literature, ASA was given in 8/12 of reported cases with
LNB-associated childhood stroke. Bleeding complications are not mentioned in the
LNB cases reported in the literature. Platelet inhibition with ASA is
recommended in childhood AIS, with a maintenance for 2&#x02009;years to cover the period
of most likely stroke recurrence.<sup>
<xref rid="bibr19-17562864221102842" ref-type="bibr">19</xref>
</sup> This recommendation should generally be followed in LNB-associated AIS,
as childhood AIS due to intracranial FCA is reported to have a high risk of recurrence.<sup>
<xref rid="bibr30-17562864221102842" ref-type="bibr">30</xref>
</sup> In addition, extracranial duplex sonography and TCCS should be performed
at outpatient follow-up visits to detect recurrence of FCA or residual long-term
vascular pathology that may warrant a longer duration of platelet
inhibition.</p><p>In patient 2, partial BA reocclusion occurred in spite of prompt platelet
inhibition with ASA, and antibiotic and anti-inflammatory treatments. Vessel
patency was restored following platelet inhibitory therapy with the Glycoprotein
IIb/IIIa antagonist tirofiban. This treatment attempt for progressive thrombotic
stroke has been described in non-controlled case series in adults<sup>
<xref rid="bibr31-17562864221102842" ref-type="bibr">31</xref>
</sup> and appeared to be safe in combination with EVT in a multicenter cohort study.<sup>
<xref rid="bibr32-17562864221102842" ref-type="bibr">32</xref>
</sup> A recent meta-analysis suggests that tirofiban does not increase the risk
of sICH in adult stroke patients treated with EVT.<sup>
<xref rid="bibr33-17562864221102842" ref-type="bibr">33</xref>
</sup> Treatment of progressive thrombotic vessel occlusion with tirofiban in
childhood AIS has not been reported in the literature and is not mentioned in
current guidelines. Currently, there is no approved indication for tirofiban in
stroke treatment. This treatment should be administered only after careful
interdisciplinary consultation and discussion of potential complications such as
bleeding and thrombocytopenia with the patient&#x02018;s legal representatives. In the
present case, the rationale was to rapidly reverse and prevent further
rethrombosis triggered by the inflamed vessel wall, as thrombectomy alone does
not resolve the underlying cause of thrombus formation in inflammatory or
infectious FCA.</p></sec><sec id="section13-17562864221102842"><title>Anti-inflammatory treatment</title><p>The two cases of childhood vertebrobasilar stroke due to early LNB described in
the present report exhibit features of LNB-associated infectious and
inflammatory FCA as described in the literature. Patient 1 showed a minimum
irregularity in the diameter of the proximal BA. However, the localization of
infarctions in the left and later right medulla oblongata is suggestive of local
vascular pathology in medullary branches of the BA. Patient 2 showed total BA
occlusion and later reocclusion and stenosis of the left PCA (P1 segment); FCA
of the BA, and PCA is supported by MR-angiography and TCCS. 9/12 of reported
cases showed involvement of the posterior circulation, a feature discussed as a
predominantly basal leptomeningeal obliterative inflammatory vasculopathy (endarteritis).<sup>
<xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>
</sup> All case reports published in the last 20&#x02009;years agree on the
inflammatory, vasculitic, or arteritic origin<sup>
<xref rid="bibr34-17562864221102842" ref-type="bibr">34</xref>
</sup> of FCA leading to stroke observed in LNB. A closer look reveals
considerable uncertainty in the concept of LNB-associated vasculitis. Although
perivascular inflammatory infiltrates without vessel wall necrosis have been
described in histopathological specimens,<sup>
<xref rid="bibr35-17562864221102842" ref-type="bibr">35</xref>
</sup> and focal MRI enhancement of the vessel wall as a controversial sign of
vasculitis was observed in 3/12 of reported cases,<sup><xref rid="bibr2-17562864221102842" ref-type="bibr">2</xref>,<xref rid="bibr11-17562864221102842" ref-type="bibr">11</xref>,<xref rid="bibr15-17562864221102842" ref-type="bibr">15</xref></sup> these observations do not
fulfill strict criteria of vasculitis. In a larger review of 88 LNB-associated
strokes in adults, only 4 patients are reported to have biopsy-proven cerebral
vasculitis, without histopathological details.<sup>
<xref rid="bibr5-17562864221102842" ref-type="bibr">5</xref>
</sup> As biopsy with demonstration of fibrinoid necrosis or inflammatory
infiltrate of all layers of the vessel wall is the diagnostic gold standard of
cerebral vasculitis,<sup>
<xref rid="bibr36-17562864221102842" ref-type="bibr">36</xref>
</sup> a general classification of LNB-associated stroke as cerebral vasculitis
is speculative. Further research on the pathophysiology of LNB-associated stroke
is needed. The present cases show features of FCA but not the typically
multifocal, beaded signs of vasculitic arteriopathy seen in most forms of
cerebral vasculitis. The LNB-associated strokes in the presented cases can be
attributed to a treatable FCA of infectious and inflammatory origin (FCA-i), and
thrombotic vessel occlusion. This eventually thrombotic pathogenesis of stroke
in LNB is in line with the original microscopical findings of Miklossy, who
described &#x02018;complete obstruction of some leptomeningeal vessels by organized
thrombus, leading to small medullary infarcts. Only in a few of (the examined
posterior circulation vessels) was partial lymphocytic infiltration of the
vessel wall also seen&#x02019;.<sup>
<xref rid="bibr35-17562864221102842" ref-type="bibr">35</xref>
</sup></p><p>As a consequence of this uncertainty in the pathogenetic classification of
LNB-associated stroke and since steroids could impair the immune response, the
use of steroids is controversial. Suppression of the immune response in
infectious diseases may both prevent tissue damage and facilitate spreading of
the infectious agent, depending strongly on the specific mechanisms of disease.
Thus, in the absence of clinical trial data, the use of steroids in LNB based on
speculative mechanisms of disease cannot be generally recommended. If steroid
treatment is initiated, it should be tapered rapidly and long-term steroid
medication should be avoided. This is reflected in the literature, as steroids
in addition to antibiotic therapy were given in 5/12 of reported cases only. The
European Federation of Neurological Societies (EFNS) guidelines do not discuss
anti-inflammatory treatment for LNB-associated stroke; for LNB, in general, it
does not support the use of steroids because of the lack of sufficient data.<sup>
<xref rid="bibr4-17562864221102842" ref-type="bibr">4</xref>
</sup> The current German guidelines on LNB discuss steroids for LNB-associated
vasculitis as class IV evidence without a clear recommendation.<sup>
<xref rid="bibr3-17562864221102842" ref-type="bibr">3</xref>
</sup></p></sec><sec id="section14-17562864221102842"><title>Limitations</title><p>The present study has clear limitations as only two cases are presented.
Comparison to the published literature is limited as most case reports were
published in a period of changing awareness of acute childhood AIS and of
hyperacute treatment possibilities.</p></sec></sec><sec sec-type="conclusions" id="section15-17562864221102842"><title>Conclusion</title><p>On the level of case-based considerations, LNB-associated FCA should not be
considered a medical contraindication for reperfusion therapies such as IVT and EVT
in childhood AIS. As the etiology of AIS is usually unknown in the hyperacute phase,
the decision should rather be in favor of IVT and EVT, even if LNB is suspected on
admission. Early antibiotic treatment is indicated. An anti-inflammatory treatment
attempt with steroids is discussed controversially in inflammatory FCA due to LNB.
Given the high risk of rethrombosis after successful reperfusion therapy of
inflammatory FCA, intensified antiplatelet regimes may be considered and early
secondary prophylaxis with ASA is recommended.</p></sec></body><back><ack><p>We thank T. Eller, Bad Salzuflen, D for his support and advice in the Borrelia
burgdorferi&#x02013;specific cerebrospinal fluid (CSF) diagnostic.</p></ack><fn-group><fn fn-type="other"><p><bold>Consent for publication:</bold> Written informed consent for publication was obtained from both patients&#x02019; legal
representatives. The need for further institutional approval was waived in
accordance with German ethical regulations on case reports.</p></fn><fn fn-type="con"><p><bold>Author contributions:</bold>
<bold>Joerg Philipps:</bold> Conceptualization; Investigation; Methodology;
Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p><p><bold>Bernhard Erdlenbruch:</bold> Investigation; Methodology; Supervision;
Writing &#x02013; review &#x00026; editing.</p><p><bold>Michael Kuschnerow:</bold> Conceptualization; Investigation; Methodology;
Writing &#x02013; original draft; Writing &#x02013; review &#x00026; editing.</p><p><bold>Sunil Jagoda:</bold> Investigation; Methodology; Writing &#x02013; original draft;
Writing &#x02013; review &#x00026; editing.</p><p><bold>Blerta Salihaj:</bold> Investigation; Writing &#x02013; original draft; Writing &#x02013;
review &#x00026; editing.</p><p><bold>J&#x000f6;rg Glahn:</bold> Investigation; Supervision; Writing &#x02013; review &#x00026;
editing.</p><p><bold>Peter Dieter Schellinger:</bold> Conceptualization; Investigation;
Methodology; Supervision; Writing &#x02013; original draft; Writing &#x02013; review &#x00026;
editing.</p></fn><fn fn-type="other"><p><bold>ORCID iD:</bold> Joerg Philipps <inline-graphic xlink:href="10.1177_17562864221102842-img1.jpg"/>
<ext-link xlink:href="https://orcid.org/0000-0003-3327-3550" ext-link-type="uri">https://orcid.org/0000-0003-3327-3550</ext-link></p></fn><fn fn-type="financial-disclosure"><p><bold>Funding:</bold> The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: We acknowledge support
by the Open Access Publication Funds of the Ruhr-University Bochum.</p></fn><fn fn-type="COI-statement"><p><bold>Conflict of interest statement:</bold> The authors declared no potential conflicts of interest with respect to the
research, authorship, and/or publication of this article.</p></fn></fn-group><ref-list><title>References</title><ref id="bibr1-17562864221102842"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Hutchinson</surname><given-names>ML</given-names></name>
<name><surname>Beslow</surname><given-names>LA</given-names></name>
<name><surname>Shih</surname><given-names>EK</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Endovascular and thrombolytic treatment eligibility in childhood
arterial ischemic stroke</article-title>. <source>Eur J Paediatr
Neurol</source>
<year>2021</year>; <volume>34</volume>:
<fpage>99</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">34454335</pub-id></mixed-citation></ref><ref id="bibr2-17562864221102842"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Monteventi</surname><given-names>O</given-names></name>
<name><surname>Steinlin</surname><given-names>M</given-names></name>
<name><surname>Regenyi</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Pediatric stroke related to Lyme neuroborreliosis: data from the
Swiss NeuroPaediatric Stroke Registry and literature review</article-title>.
<source>Eur J Paediatr Neurol</source>
<year>2018</year>; <volume>22</volume>:
<fpage>113</fpage>&#x02013;<lpage>121</lpage>.<pub-id pub-id-type="pmid">29208342</pub-id></mixed-citation></ref><ref id="bibr3-17562864221102842"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rauer</surname><given-names>S</given-names></name>
<name><surname>Kastenbauer</surname><given-names>S</given-names></name>
<name><surname>Hofmann</surname><given-names>H</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Guidelines for diagnosis and treatment in neurology &#x02013; Lyme
neuroborreliosis</article-title>. <source>Ger Med Sci</source>
<year>2020</year>; <volume>18</volume>: Doc03.</mixed-citation></ref><ref id="bibr4-17562864221102842"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mygland</surname><given-names>A</given-names></name>
<name><surname>Ljostad</surname><given-names>U</given-names></name>
<name><surname>Fingerle</surname><given-names>V</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>EFNS guidelines on the diagnosis and management of European Lyme
neuroborreliosis</article-title>. <source>Eur J Neurol</source>
<year>2010</year>; <volume>17</volume>: <fpage>8</fpage>&#x02013;<lpage>16</lpage>,
e1&#x02013;e4.<pub-id pub-id-type="pmid">19930447</pub-id></mixed-citation></ref><ref id="bibr5-17562864221102842"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Garkowski</surname><given-names>A</given-names></name>
<name><surname>Zajkowska</surname><given-names>J</given-names></name>
<name><surname>Zajkowska</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Cerebrovascular manifestations of Lyme neuroborreliosis &#x02013; a
systematic review of published cases</article-title>. <source>Front
Neurol</source>
<year>2017</year>; <volume>8</volume>: <fpage>146</fpage>.<pub-id pub-id-type="pmid">28473801</pub-id></mixed-citation></ref><ref id="bibr6-17562864221102842"><label>6</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gagnier</surname><given-names>JJ</given-names></name>
<name><surname>Kienle</surname><given-names>G</given-names></name>
<name><surname>Altman</surname><given-names>DG</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>The CARE guidelines: consensus-based clinical case reporting
guideline development</article-title>. <source>Glob Adv Health Med</source>
<year>2013</year>; <volume>2</volume>:
<fpage>38</fpage>&#x02013;<lpage>43</lpage>.</mixed-citation></ref><ref id="bibr7-17562864221102842"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Moher</surname><given-names>D</given-names></name>
<name><surname>Liberati</surname><given-names>A</given-names></name>
<name><surname>Tetzlaff</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Preferred reporting items for systematic reviews and
meta-analyses: the PRISMA statement</article-title>. <source>BMJ</source>
<year>2009</year>; <volume>339</volume>: <fpage>b2535</fpage>.<pub-id pub-id-type="pmid">19622551</pub-id></mixed-citation></ref><ref id="bibr8-17562864221102842"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Klingebiel</surname><given-names>R</given-names></name>
<name><surname>Benndorf</surname><given-names>G</given-names></name>
<name><surname>Schmitt</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Large cerebral vessel occlusive disease in Lyme
neuroborreliosis</article-title>. <source>Neuropediatrics</source>
<year>2002</year>; <volume>33</volume>:
<fpage>37</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">11930275</pub-id></mixed-citation></ref><ref id="bibr9-17562864221102842"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Cox</surname><given-names>MG</given-names></name>
<name><surname>Wolfs</surname><given-names>TF</given-names></name>
<name><surname>Lo</surname><given-names>TH</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Neuroborreliosis causing focal cerebral arteriopathy in a
child</article-title>. <source>Neuropediatrics</source>
<year>2005</year>; <volume>36</volume>:
<fpage>104</fpage>&#x02013;<lpage>107</lpage>.<pub-id pub-id-type="pmid">15822023</pub-id></mixed-citation></ref><ref id="bibr10-17562864221102842"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>R&#x000e9;nard</surname><given-names>C</given-names></name>
<name><surname>Marignier</surname><given-names>S</given-names></name>
<name><surname>Gillet</surname><given-names>Y</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>[Acute hemiparesis revealing a neuroborreliosis in a
child]</article-title>. <source>Arch Pediatr</source>
<year>2008</year>; <volume>15</volume>:
<fpage>41</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">18155890</pub-id></mixed-citation></ref><ref id="bibr11-17562864221102842"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Lebas</surname><given-names>A</given-names></name>
<name><surname>Toulgoat</surname><given-names>F</given-names></name>
<name><surname>Saliou</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Stroke due to Lyme neuroborreliosis: changes in vessel wall
contrast enhancement</article-title>. <source>J Neuroimaging</source>
<year>2012</year>; <volume>22</volume>:
<fpage>210</fpage>&#x02013;<lpage>212</lpage>.<pub-id pub-id-type="pmid">21122000</pub-id></mixed-citation></ref><ref id="bibr12-17562864221102842"><label>12</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kohns</surname><given-names>M</given-names></name>
<name><surname>Karenfort</surname><given-names>M</given-names></name>
<name><surname>Schaper</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Transient ischaemic attack in a 5-year-old girl due to focal
vasculitis in neuroborreliosis</article-title>. <source>Cerebrovasc
Dis</source>
<year>2013</year>; <volume>35</volume>:
<fpage>184</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">23429243</pub-id></mixed-citation></ref><ref id="bibr13-17562864221102842"><label>13</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Kurian</surname><given-names>M</given-names></name>
<name><surname>Pereira</surname><given-names>VM</given-names></name>
<name><surname>Vargas</surname><given-names>MI</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Stroke-like phenomena revealing multifocal cerebral vasculitis in
pediatric Lyme neuroborreliosis</article-title>. <source>J Child
Neurol</source>
<year>2015</year>; <volume>30</volume>:
<fpage>1226</fpage>&#x02013;<lpage>1229</lpage>.<pub-id pub-id-type="pmid">25316727</pub-id></mixed-citation></ref><ref id="bibr14-17562864221102842"><label>14</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Allen</surname><given-names>NM</given-names></name>
<name><surname>Jungbluth</surname><given-names>H</given-names></name>
</person-group>. <article-title>Lyme neuroborreliosis: a potentially preventable
cause of stroke</article-title>. <source>J Pediatr</source>
<year>2016</year>; <volume>170</volume>: 334&#x02013;334.e1.</mixed-citation></ref><ref id="bibr15-17562864221102842"><label>15</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Wittwer</surname><given-names>B</given-names></name>
<name><surname>Pelletier</surname><given-names>S</given-names></name>
<name><surname>Ducrocq</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Cerebrovascular events in Lyme neuroborreliosis</article-title>.
<source>J Stroke Cerebrovasc Dis</source>
<year>2015</year>; <volume>24</volume>:
<fpage>1671</fpage>&#x02013;<lpage>1678</lpage>.<pub-id pub-id-type="pmid">26002071</pub-id></mixed-citation></ref><ref id="bibr16-17562864221102842"><label>16</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Estrada-Pena</surname><given-names>A</given-names></name>
<name><surname>Cutler</surname><given-names>S</given-names></name>
<name><surname>Potkonjak</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>An updated meta-analysis of the distribution and prevalence of
Borrelia burgdorferi s.l. in ticks in Europe</article-title>. <source>Int J
Health Geogr</source>
<year>2018</year>; <volume>17</volume>: <fpage>41</fpage>.<pub-id pub-id-type="pmid">30514310</pub-id></mixed-citation></ref><ref id="bibr17-17562864221102842"><label>17</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Barstad</surname><given-names>B</given-names></name>
<name><surname>Quarsten</surname><given-names>H</given-names></name>
<name><surname>Tveitnes</surname><given-names>D</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Direct molecular detection and genotyping of Borrelia burgdorferi
Sensu Lato in cerebrospinal fluid of children with Lyme
neuroborreliosis</article-title>. <source>J Clin Microbiol</source>
<year>2018</year>; <volume>56</volume>: e01868-17.</mixed-citation></ref><ref id="bibr18-17562864221102842"><label>18</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Rivkin</surname><given-names>MJ</given-names></name>
<name><surname>deVeber</surname><given-names>G</given-names></name>
<name><surname>Ichord</surname><given-names>RN</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Thrombolysis in pediatric stroke study</article-title>.
<source>Stroke</source>
<year>2015</year>; <volume>46</volume>:
<fpage>880</fpage>&#x02013;<lpage>885</lpage>.<pub-id pub-id-type="pmid">25613306</pub-id></mixed-citation></ref><ref id="bibr19-17562864221102842"><label>19</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Ferriero</surname><given-names>DM</given-names></name>
<name><surname>Fullerton</surname><given-names>HJ</given-names></name>
<name><surname>Bernard</surname><given-names>TJ</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Management of stroke in neonates and children: a scientific
statement from the American Heart Association/American Stroke
Association</article-title>. <source>Stroke</source>
<year>2019</year>; <volume>50</volume>:
<fpage>e51</fpage>&#x02013;<lpage>e96</lpage>.<pub-id pub-id-type="pmid">30686119</pub-id></mixed-citation></ref><ref id="bibr20-17562864221102842"><label>20</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Amlie-Lefond</surname><given-names>C</given-names></name>
<name><surname>Shaw</surname><given-names>DWW</given-names></name>
<name><surname>Cooper</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Risk of intracranial hemorrhage following intravenous tPA
(tissue-type plasminogen activator) for acute stroke is low in
children</article-title>. <source>Stroke</source>
<year>2020</year>; <volume>51</volume>:
<fpage>542</fpage>&#x02013;<lpage>548</lpage>.<pub-id pub-id-type="pmid">31842706</pub-id></mixed-citation></ref><ref id="bibr21-17562864221102842"><label>21</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Olivieri</surname><given-names>M</given-names></name>
<name><surname>Sorg</surname><given-names>AL</given-names></name>
<name><surname>Weinberger</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Recanalization strategies in childhood stroke in
Germany</article-title>. <source>Sci Rep</source>
<year>2021</year>; <volume>11</volume>: <fpage>13314</fpage>.<pub-id pub-id-type="pmid">34172782</pub-id></mixed-citation></ref><ref id="bibr22-17562864221102842"><label>22</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>van Es</surname><given-names>ACGM</given-names></name>
<name><surname>Hunfeld</surname><given-names>MAW</given-names></name>
<name><surname>van den Wijngaard</surname><given-names>I</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Endovascular treatment for acute ischemic stroke in children:
experience from the MR CLEAN Registry</article-title>.
<source>Stroke</source>
<year>2021</year>; <volume>52</volume>:
<fpage>781</fpage>&#x02013;<lpage>788</lpage>.<pub-id pub-id-type="pmid">33617341</pub-id></mixed-citation></ref><ref id="bibr23-17562864221102842"><label>23</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sun</surname><given-names>LR</given-names></name>
<name><surname>Harrar</surname><given-names>D</given-names></name>
<name><surname>Drocton</surname><given-names>G</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Mechanical thrombectomy for acute ischemic stroke: considerations
in children</article-title>. <source>Stroke</source>
<year>2020</year>; <volume>51</volume>:
<fpage>3174</fpage>&#x02013;<lpage>3181</lpage>.<pub-id pub-id-type="pmid">32912096</pub-id></mixed-citation></ref><ref id="bibr24-17562864221102842"><label>24</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Sporns</surname><given-names>PB</given-names></name>
<name><surname>Kemmling</surname><given-names>A</given-names></name>
<name><surname>Hanning</surname><given-names>U</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Thrombectomy in childhood stroke</article-title>. <source>J Am
Heart Assoc</source>
<year>2019</year>; <volume>8</volume>: <fpage>e011335</fpage>.<pub-id pub-id-type="pmid">30803281</pub-id></mixed-citation></ref><ref id="bibr25-17562864221102842"><label>25</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Arnold</surname><given-names>M</given-names></name>
<name><surname>Steinlin</surname><given-names>M</given-names></name>
<name><surname>Baumann</surname><given-names>A</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Thrombolysis in childhood stroke: report of 2 cases and review of
the literature</article-title>. <source>Stroke</source>
<year>2009</year>; <volume>40</volume>:
<fpage>801</fpage>&#x02013;<lpage>807</lpage>.<pub-id pub-id-type="pmid">19118242</pub-id></mixed-citation></ref><ref id="bibr26-17562864221102842"><label>26</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bigi</surname><given-names>S</given-names></name>
<name><surname>Dulcey</surname><given-names>A</given-names></name>
<name><surname>Gralla</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Feasibility, safety, and outcome of recanalization treatment in
childhood stroke</article-title>. <source>Ann Neurol</source>
<year>2018</year>; <volume>83</volume>:
<fpage>1125</fpage>&#x02013;<lpage>1132</lpage>.<pub-id pub-id-type="pmid">29679441</pub-id></mixed-citation></ref><ref id="bibr27-17562864221102842"><label>27</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Roach</surname><given-names>ES</given-names></name>
<name><surname>Golomb</surname><given-names>MR</given-names></name>
<name><surname>Adams</surname><given-names>R</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Management of stroke in infants and children: a scientific
statement from a Special Writing Group of the American Heart Association
Stroke Council and the Council on Cardiovascular Disease in the
Young</article-title>. <source>Stroke</source>
<year>2008</year>; <volume>39</volume>:
<fpage>2644</fpage>&#x02013;<lpage>2691</lpage>.<pub-id pub-id-type="pmid">18635845</pub-id></mixed-citation></ref><ref id="bibr28-17562864221102842"><label>28</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Gerstl</surname><given-names>L</given-names></name>
<name><surname>Bonfert</surname><given-names>MV</given-names></name>
<name><surname>Heinen</surname><given-names>F</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Childhood arterial ischaemic stroke: clinical presentation, risk
factors and management</article-title>. <source>Hamostaseologie</source>
<year>2020</year>; <volume>40</volume>:
<fpage>165</fpage>&#x02013;<lpage>173</lpage>.<pub-id pub-id-type="pmid">32325521</pub-id></mixed-citation></ref><ref id="bibr29-17562864221102842"><label>29</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Naggara</surname><given-names>O</given-names></name>
<name><surname>Raymond</surname><given-names>J</given-names></name>
<name><surname>Domingo Ayllon</surname><given-names>M</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>T2* &#x02018;susceptibility vessel sign&#x02019; demonstrates clot location and
length in acute ischemic stroke</article-title>. <source>PLoS ONE</source>
<year>2013</year>; <volume>8</volume>: <fpage>e76727</fpage>.<pub-id pub-id-type="pmid">24146915</pub-id></mixed-citation></ref><ref id="bibr30-17562864221102842"><label>30</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Bohmer</surname><given-names>M</given-names></name>
<name><surname>Niederstadt</surname><given-names>T</given-names></name>
<name><surname>Heindel</surname><given-names>W</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Impact of childhood arterial ischemic stroke standardized
classification and diagnostic evaluation classification on further course of
arteriopathy and recurrence of childhood stroke</article-title>.
<source>Stroke</source>. Epub ahead of print <day>7</day>
<month>December</month>
<year>2018</year>. DOI: <pub-id pub-id-type="doi">10.1161/STROKEAHA.118.023060.</pub-id></mixed-citation></ref><ref id="bibr31-17562864221102842"><label>31</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Mangiafico</surname><given-names>S</given-names></name>
<name><surname>Cellerini</surname><given-names>M</given-names></name>
<name><surname>Nencini</surname><given-names>P</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Intravenous tirofiban with intra-arterial urokinase and
mechanical thrombolysis in stroke: preliminary experience in 11
cases</article-title>. <source>Stroke</source>
<year>2005</year>; <volume>36</volume>:
<fpage>2154</fpage>&#x02013;<lpage>2158</lpage>.<pub-id pub-id-type="pmid">16141418</pub-id></mixed-citation></ref><ref id="bibr32-17562864221102842"><label>32</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L</given-names></name>
<name><surname>Jian</surname><given-names>Y</given-names></name>
<name><surname>Li</surname><given-names>T</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>The safety and efficiency of tirofiban in acute ischemic stroke
patients treated with mechanical thrombectomy: a multicenter retrospective
cohort study</article-title>. <source>Biochem Res Int</source>
<year>2020</year>; <volume>2020</volume>:
<fpage>5656173</fpage>.<pub-id pub-id-type="pmid">32399299</pub-id></mixed-citation></ref><ref id="bibr33-17562864221102842"><label>33</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Z</given-names></name>
<name><surname>Xu</surname><given-names>C</given-names></name>
<name><surname>Liu</surname><given-names>X</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Safety and efficacy of tirofiban in acute ischemic stroke
patients receiving endovascular treatment: a meta-analysis</article-title>.
<source>Cerebrovasc Dis</source>
<year>2020</year>; <volume>49</volume>:
<fpage>442</fpage>&#x02013;<lpage>450</lpage>.<pub-id pub-id-type="pmid">32731250</pub-id></mixed-citation></ref><ref id="bibr34-17562864221102842"><label>34</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Parikh</surname><given-names>NS</given-names></name>
<name><surname>Merkler</surname><given-names>AE</given-names></name>
<name><surname>Iadecola</surname><given-names>C</given-names></name>
</person-group>. <article-title>Inflammation, autoimmunity, infection, and
stroke: epidemiology and lessons from therapeutic
intervention</article-title>. <source>Stroke</source>
<year>2020</year>; <volume>51</volume>:
<fpage>711</fpage>&#x02013;<lpage>718</lpage>.<pub-id pub-id-type="pmid">32078460</pub-id></mixed-citation></ref><ref id="bibr35-17562864221102842"><label>35</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Miklossy</surname><given-names>J</given-names></name>
<name><surname>Kuntzer</surname><given-names>T</given-names></name>
<name><surname>Bogousslavsky</surname><given-names>J</given-names></name>
</person-group>, <etal>et al</etal>
<article-title>Meningovascular form of neuroborreliosis: similarities between
neuropathological findings in a case of Lyme disease and those occurring in
tertiary neurosyphilis</article-title>. <source>Acta Neuropathol</source>
<year>1990</year>; <volume>80</volume>:
<fpage>568</fpage>&#x02013;<lpage>572</lpage>.<pub-id pub-id-type="pmid">2251916</pub-id></mixed-citation></ref><ref id="bibr36-17562864221102842"><label>36</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<name><surname>Berlit</surname><given-names>P</given-names></name>
</person-group>. <article-title>Diagnosis and treatment of cerebral
vasculitis</article-title>. <source>Ther Adv Neurol Disord</source>
<year>2010</year>; <volume>3</volume>:
<fpage>29</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">21180634</pub-id></mixed-citation></ref></ref-list></back></article>
